Autor: |
Xingjian Niu, Jianli Ma, Jingtong Li, Yucui Gu, Lei Yin, Yiran Wang, Xiaoping Zhou, Jinlu Wang, Hongfei Ji, Qingyuan Zhang |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
Cell Death and Disease, Vol 12, Iss 6, Pp 1-15 (2021) |
Druh dokumentu: |
article |
ISSN: |
2041-4889 |
DOI: |
10.1038/s41419-021-03781-x |
Popis: |
Abstract Endocrine therapy is the standard treatment for estrogen receptor (ER)-positive breast cancer, but tumors eventually develop resistance. However, endocrine therapy resistance mechanisms mediated through interactions between breast cancer cells and tumor-associated macrophages (TAMs) are still unclear. Here, we characterized sodium/glucose cotransporter 1 (SGLT1) overexpression drives the highly glycolytic phenotype of tamoxifen-resistant breast cancer cells where enhanced lactic acid secretion promotes M2-like TAM polarization via the hypoxia-inducible factor-1α/signal transducer and activator of transcription-3 pathway. In turn, M2-like TAMs activate breast cancer cells through EGFR/PI3K/Akt signaling, providing feedback to upregulate SGLT1 and promote tamoxifen resistance and accelerate tumor growth in vitro and in vivo. Higher expression of SGLT1 and CD163+ TAMs was associated with endocrine-resistant ER-positive breast cancers. Our study identifies a novel vicious cycle of metabolic reprogramming, M2-like TAM polarization, and endocrine therapy resistance, which involves SGLT1, proposing SGLT1 as a therapeutic target to overcome endocrine therapy resistance in breast cancer. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|